Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House panel limits CE research

This article was originally published in The Gray Sheet

Executive Summary

In a last-minute markup session on health reform legislation before breaking for its August recess, the House Energy and Commerce Committee agreed by voice vote to limits on comparative effectiveness research. One amendment, offered by Rep. Mike Rogers, R-Mich., states that the research cannot be used to deny or ration care. A second amendment from Rep. Phil Gingrey, R-Ga., specifies that CMS cannot base coverage decisions on federally funded clinical comparative effectiveness research. At press time, markup on the bill was expected to be completed, and the entire package approved by the panel, before the House recessed. The Senate Finance Committee said July 31 it will not vote on its version of health reform until the Senate returns from its recess in September

You may also be interested in...



As Health Reform Advanced, Device Firms Spent Heavily On Blue Dogs

Device firms have spent heavily on members of Congress seeking to slow the progress and limit the scope of health care reform legislation, according to lobbying contribution records maintained by the clerk of the House and secretary of the Senate

House Health Reform Amendments Round-Up: AAA Screening Report, No IMAC

Amendments to ban reduced payments for pain treatments and make screenings for aneurysms a priority are just two provisions added to a health reform bill during the House Energy and Commerce Committee's marathon mark-up sessions July 30 and 31

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Topics

UsernamePublicRestriction

Register

MT027740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel